Literature DB >> 24163366

Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.

Erin E Congdon1, Jiaping Gu, Hameetha B R Sait, Einar M Sigurdsson.   

Abstract

Tau immunotherapy is effective in transgenic mice, but the mechanisms of Tau clearance are not well known. To this end, Tau antibody uptake was analyzed in brain slice cultures and primary neurons. Internalization was rapid (<1 h), saturable, and substantial compared with control mouse IgG. Furthermore, temperature reduction to 4 °C, an excess of unlabeled mouse IgG, or an excess of Tau antibodies reduced uptake in slices by 63, 41, and 62%, respectively (p = 0.002, 0.04, and 0.005). Uptake strongly correlated with total and insoluble Tau levels (r(2) = 0.77 and 0.87 and p = 0.002 and 0.0002), suggesting that Tau aggregates influence antibody internalization and/or retention within neurons. Inhibiting phagocytosis did not reduce uptake in slices or neuronal cultures, indicating limited microglial involvement. In contrast, clathrin-specific inhibitors reduced uptake in neurons (≤ 78%, p < 0.0001) and slices (≤ 35%, p = 0.03), demonstrating receptor-mediated endocytosis as the primary uptake pathway. Fluid phase endocytosis accounted for the remainder of antibody uptake in primary neurons, based on co-staining with internalized dextran. The receptor-mediated uptake is to a large extent via low affinity FcγII/III receptors and can be blocked in slices (43%, p = 0.04) and neurons (53%, p = 0.008) with an antibody against these receptors. Importantly, antibody internalization appears to be necessary for Tau reduction in primary neurons. Overall, these findings clarify that Tau antibody uptake is primarily receptor-mediated, that these antibodies are mainly found in neurons with Tau aggregates, and that their intracellular interaction leads to clearance of Tau pathology, all of which have major implications for therapeutic development of this approach.

Entities:  

Keywords:  Alzheimer Disease; Antibodies; Endocytosis; Immunotherapy; Tau

Mesh:

Substances:

Year:  2013        PMID: 24163366      PMCID: PMC3853292          DOI: 10.1074/jbc.M113.491001

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

Authors:  Pritam Das; Victor Howard; Nicole Loosbrock; Dennis Dickson; M Paul Murphy; Todd E Golde
Journal:  J Neurosci       Date:  2003-09-17       Impact factor: 6.167

2.  Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.

Authors:  Jiaping Gu; Erin E Congdon; Einar M Sigurdsson
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

3.  Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.

Authors:  K Duff; C Eckman; C Zehr; X Yu; C M Prada; J Perez-tur; M Hutton; L Buee; Y Harigaya; D Yager; D Morgan; M N Gordon; L Holcomb; L Refolo; B Zenk; J Hardy; S Younkin
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

Review 4.  Endocytosis.

Authors:  S C Silverstein; R M Steinman; Z A Cohn
Journal:  Annu Rev Biochem       Date:  1977       Impact factor: 23.643

5.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

6.  Phosphorylation-independent ubiquitylation and endocytosis of Fc gammaRIIA.

Authors:  Patricia Mero; Christine Y Zhang; Zhen-Yu Huang; Moo-Kyung Kim; Alan D Schreiber; Sergio Grinstein; James W Booth
Journal:  J Biol Chem       Date:  2006-09-07       Impact factor: 5.157

Review 7.  Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Authors:  Delphine Boche; Nathan Denham; Clive Holmes; James A R Nicoll
Journal:  Acta Neuropathol       Date:  2010-07-15       Impact factor: 17.088

8.  Fcgamma receptors contribute to pyramidal cell death in the mouse hippocampus following local kainic acid injection.

Authors:  S Suemitsu; M Watanabe; E Yokobayashi; S Usui; T Ishikawa; Y Matsumoto; N Yamada; M Okamoto; S Kuroda
Journal:  Neuroscience       Date:  2010-01-13       Impact factor: 3.590

9.  Trans-synaptic spread of tau pathology in vivo.

Authors:  Li Liu; Valerie Drouet; Jessica W Wu; Menno P Witter; Scott A Small; Catherine Clelland; Karen Duff
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

10.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824

View more
  85 in total

Review 1.  [Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets].

Authors:  M A Busche; M Staufenbiel; M Willem; C Haass; H Förstl
Journal:  Nervenarzt       Date:  2016-11       Impact factor: 1.214

2.  Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro.

Authors:  Chloe K Nobuhara; Sarah L DeVos; Caitlin Commins; Susanne Wegmann; Benjamin D Moore; Allyson D Roe; Isabel Costantino; Matthew P Frosch; Rose Pitstick; George A Carlson; Christoph Hock; Roger M Nitsch; Fabio Montrasio; Jan Grimm; Anne E Cheung; Anthone W Dunah; Marion Wittmann; Thierry Bussiere; Paul H Weinreb; Bradley T Hyman; Shuko Takeda
Journal:  Am J Pathol       Date:  2017-04-11       Impact factor: 4.307

Review 3.  Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.

Authors:  Senthilkumar Krishnaswamy; Huai-Wei Huang; Isabella S Marchal; Hyung Don Ryoo; Einar M Sigurdsson
Journal:  Neurobiol Dis       Date:  2020-01-23       Impact factor: 5.996

4.  Neuropathogenesis of Zika Virus Infection : Potential Roles of Antibody-Mediated Pathology.

Authors:  Ikuo Tsunoda; Seiichi Omura; Fumitaka Sato; Susumu Kusunoki; Mitsugu Fujita; Ah-Mee Park; Faris Hasanovic; Richard Yanagihara; Satoshi Nagata
Journal:  Acta Med Kinki Univ       Date:  2016

5.  Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach.

Authors:  Dov B Shamir; Nina Rosenqvist; Suhail Rasool; Jan T Pedersen; Einar M Sigurdsson
Journal:  Alzheimers Dement       Date:  2016-03-23       Impact factor: 21.566

Review 6.  Immunotherapeutic approaches for Alzheimer's disease.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Neuron       Date:  2015-03-18       Impact factor: 17.173

Review 7.  Immunotherapy for Alzheimer's disease.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

Review 8.  Harnessing the immune system for treatment and detection of tau pathology.

Authors:  Erin E Congdon; Senthilkumar Krishnaswamy; Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 10.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.